TARA’s technology approach forms the basis for reliable and predictive testing on new medicines

down

Vision

Relevant pre-clinical heart models used for cardiotoxicity testing. As a result, currently 8 out of 9 drugs tested for cardiotoxicity fail in clinical trials, after spending significant time and money and exposing patients to substantial risks.

Platform

BiowireTM II: The Next GenerationIn Vitro Human Cardiac Model

Currently, new medicine development requires substantial time and capital, and yet medicines face frequent withdrawal from the market due to cardiovascular complications. Cell culture and animal testing models are unable to adequately predict drug effects seen in patients.

TARA’s innovative platform represents a leap forward

platform1

TARA uses stem cells, obtained from skin, to produce heart cells.

platform2

TARA’s Biowire platform stimulates the heart cellsto make mature heart tissues.

platform3

The TARA tissues mimic adult hearts so that realistic changes in human cardiac function can be measured without human testing.

platform4

TARA can measure the key function of the heart to understand changes in the rate of heartbeat, the calcium handling governing the heartbeat and the force of the heartbeat.

TARA tissue in action

heartbeat

Download TARA Datasheet

NEWS

TARA Biosystems Named Red Herring Top 100 of 2017

June 14, 2017. Red Herring has announced the winners of its Top 100 North America 2017 event, held this week in Los Angeles. The winning companies, selected from thousands of prospective startups and tech firms, represent the cutting edge of North America’s world-class technology industry–and demonstrate the region’s continued reputation …

read more

Thirteen startups join Springboard’s Health Innovation Hub

April 18, 2017.   A new batch of 13 women-led life science and healthcare startups have been accepted into Springboard Enterprises’ Health Innovation Hub, a year-long program for growth-stage companies preparing to expand and raise funds for new product development. It’s an opportunity for guidance, networking, and access to new …

read more

TARA Biosystems Founder Appointed University Professor

April 17, 2017. Gordana Vunjak-Novakovic, PhD, the Mikati Foundation Professor of Biomedical Engineering, professor of medical sciences at P&S, and director of Columbia’s Laboratory for Stem Cells and Tissue Engineering at CUMC, has been appointed a University Professor, Columbia University’s highest academic honor. The medical center now has five faculty …

read more

New York City’s Burgeoning Biotech Industry

December 7, 2016. New buildings on the East Side of Manhattan are signs of life of the city’s foray into a new economy, its burgeoning biotech industry. NY1’s Erin Billups filed the following report. New York is known for many things. The biotech industry is not one of them. But …

read more

BBC World News Interviews TARA Biosystems Founder

November 14, 2016. Need a new body part? New blood? New bone, new heart? Well in the future you may be able to order one. Scientists and technologists are working towards a bio-engineered future where new tissues and new organs could be made to order. We are looking at the …

read more

TARA Biosystems Appoints Robert Langer to Board of Directors

June 22, 2016. NEW YORK–(BUSINESS WIRE)–TARA Biosystems, Inc., a company developing physiologically relevant “heart-on-a-chip” tissue models for both toxicology and drug discovery applications, announced today that it has appointed biotechnology entrepreneur, scientist and engineer Robert S. Langer, Ph.D., to its board of directors. read more TARA Biosystems offers testing services …

read more

Interview with Founder of TARA Biosystems.

April 28, 2016. biomedical engineering postdocs who trick skin cells into becoming stem cells, from which tissue engineers grow miniature versions of human organs that can safely screen new drugs and treat diseases. Think: organ on a chip. read more

read more

TARA Biosystems Raises Seed Funding

NEW YORK, Jan. 05, 2016 (GLOBE NEWSWIRE) — TARA Biosystems, Inc., which provides physiologically-relevant “heart-on-a-chip” tissue models for both toxicology and drug discovery applications, raised $2.25 million in a seed financing to build commercial operations in New York City. Based on research from the laboratories of Columbia University Professor Gordana …

read more

Markets

As a result, currently 8 out of 9 drugs tested for cardiotoxicity fail in clinical trials, after spending significant time.

lungs

Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group.

pills

Dr. Ushio has over 20 years of experience in the biotechnology and pharmaceutical industry, and early stage life science company building.

chart

Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines.

Team

As a result, currently 8 out of 9 drugs tested for cardiotoxicity fail in clinical trials, after spending significant time and money and exposing patients to substantial risks.

Dr. Doctor MD
Dr. Doctor MD Doctor Read bio
Mr. Doctor Man
Mr. Doctor Man Title of person is abnormally long in regards to number Read bio
Dr. Misti Ushio
Dr. Misti Ushio Founding CEO Read bio
whatever
whatever nothing Read bio
blank
blank null Read bio
hhhehhehehhh
hhhehhehehhh ouiouoiyoiuyoiuy Read bio

Join Us

Dr. Misti Ushio

Dr. Misti Ushio

Founding CEO

Misti Ushio, PhD. is the founding CEO of TARA Biosystems. Dr. Ushio has over 20 years of experience in the biotechnology and pharmaceutical industry, and early stage life science company building. Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she worked with, and invested in, life science companies to help them translate their transformational science into commercially successful companies.

Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines and biologics products, and Columbia University, where she managed the intellectual property of several scientific and engineering portfolios.

She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering). She also serves as a Director on the Boards of private and public life science companies.

Misti enjoys the ballet, travelling to new places and spending time at the beach with her family.

close
Dr. Doctor MD

Dr. Doctor MD

Doctor

Misti Ushio, PhD. is the founding CEO of TARA Biosystems. Dr. Ushio has over 20 years of experience in the biotechnology and pharmaceutical industry, and early stage life science company building. Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she worked with, and invested in, life science companies to help them translate their transformational science into commercially successful companies.

Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines and biologics products, and Columbia University, where she managed the intellectual property of several scientific and engineering portfolios.

She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering). She also serves as a Director on the Boards of private and public life science companies.

Misti enjoys the ballet, travelling to new places and spending time at the beach with her family.

close
Mr. Doctor Man

Mr. Doctor Man

Title of person is abnormally long in regards to number

Misti Ushio, PhD. is the founding CEO of TARA Biosystems. Dr. Ushio has over 20 years of experience in the biotechnology and pharmaceutical industry, and early stage life science company building. Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she worked with, and invested in, life science companies to help them translate their transformational science into commercially successful companies.

Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines and biologics products, and Columbia University, where she managed the intellectual property of several scientific and engineering portfolios.

She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering). She also serves as a Director on the Boards of private and public life science companies.

Misti enjoys the ballet, travelling to new places and spending time at the beach with her family.

close
whatever

whatever

nothing

Misti Ushio, PhD. is the founding CEO of TARA Biosystems. Dr. Ushio has over 20 years of experience in the biotechnology and pharmaceutical industry, and early stage life science company building. Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she worked with, and invested in, life science companies to help them translate their transformational science into commercially successful companies.

Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines and biologics products, and Columbia University, where she managed the intellectual property of several scientific and engineering portfolios.

She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering). She also serves as a Director on the Boards of private and public life science companies.

Misti enjoys the ballet, travelling to new places and spending time at the beach with her family.

close
blank

blank

null

Misti Ushio, PhD. is the founding CEO of TARA Biosystems. Dr. Ushio has over 20 years of experience in the biotechnology and pharmaceutical industry, and early stage life science company building. Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she worked with, and invested in, life science companies to help them translate their transformational science into commercially successful companies.

Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines and biologics products, and Columbia University, where she managed the intellectual property of several scientific and engineering portfolios.

She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering). She also serves as a Director on the Boards of private and public life science companies.

Misti enjoys the ballet, travelling to new places and spending time at the beach with her family.

close
hhhehhehehhh

hhhehhehehhh

ouiouoiyoiuyoiuy

Misti Ushio, PhD. is the founding CEO of TARA Biosystems. Dr. Ushio has over 20 years of experience in the biotechnology and pharmaceutical industry, and early stage life science company building. Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she worked with, and invested in, life science companies to help them translate their transformational science into commercially successful companies.

Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines and biologics products, and Columbia University, where she managed the intellectual property of several scientific and engineering portfolios.

She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering). She also serves as a Director on the Boards of private and public life science companies.

Misti enjoys the ballet, travelling to new places and spending time at the beach with her family.

close

Contact

As a result, currently 8 out of 9 drugs tested for cardiotoxicity fail in clinical trials, after spending significant time.

TARA
430 East 29th Street
Suite #1015
New York, NY 10016
USA
info@tarabiosystems.com